Q2 2013 Presentation

July 31, 2013

www.metabolix.com

@MetabolixInc

© 2013 Metabolix 2

Safe Harbor Statement*

Our presentation includes, and our response to various questions may

include, forward-looking statements about the Company’s future plans

and objectives. Any such statements are subject to risks and

uncertainties that could cause the actual results and the

implementation of the Company’s plans and operations to vary

materially. These risks are discussed in the Company’s filings with the

S.E.C., including, without limitation, our Form 10-K filed March 28,

2013.

*Under the Private Securities Litigation Reform Act of 1995

© 2013 Metabolix 3

Growth Strategy Key Drivers

Targeting advanced materials market through PHA technology

Building portfolio of biopolymer products: film, performance additives and functional biodegradation segments

Developing customer relationships in advance of commercial production

Working to establish a robust supply chain based on 10KTPA of PHA capacity

Producing highly differentiated biobased chemicals and a biorefinery system with crops through proprietary PHA technology

Creating commercial opportunities and competitive barriers through extensive IP position

© 2013 Metabolix 4

Q2 Progress – Samsung Collaboration

Collaboration Agreement with Samsung Fine Chemicals

Goal of expanding the global market for biodegradable polymers

Products designed to deliver best performance and value to targeted customer applications

All products developed will complement the product portfolios of each company

Extension of work that commenced in early 2012

Samsung MBLX

Products PBAT

PBS

Wide

Range

of PHAs

Region Asia

Australia

New Zealand

N.A.

E.U.

© 2013 Metabolix 5

Film/Bags: Building demand for Mvera B5008 compostable film

Performance Additives: Published white paper in Plastics Technology,

expanding data set and developing customer relationships in PVC

Functional Biodegradation: Delivering tailored solutions into water

treatment applications and developing latex product with partners

Q2 Progress – Biopolymers

Biopolymers

© 2013 Metabolix 6

Q2 Progress – Biobased Chemicals and Crops

Biobased Chemicals

Producing renewable-based chemicals for applications that typically relied on fossil fuels

Achieving our technical and commercial milestones in C4 and C3

Increasing interest in C3 (bioacrylic) technology

Acrylic consumers demanding biocontent

Crops

Working on several grants

Research targets multi-gene expression and plant transformation

MIT Technology Review published article highlighting our process for making PHB in switchgrass

Article available on our website

© 2013 Metabolix 7

Q2 Progress – Intellectual Property

Biopolymers

Four patents

granted / allowed;

advanced

processing of

Mirel biopolymer

resin to enhance

performance

attributes

Crops

Granted a U.S.

patent covering

production of PHB

in switchgrass

Granted / Allowed Six Patents in Q2

Patent allowed as

first in a family

covering engineered

systems to produce

biomass to convert

into C5 chemicals

© 2013 Metabolix 8

Operations Update Strengthening the Supply Chain

Near-term plan to utilize PHA biopolymers from 10KTPA plant

Focused clearly on 3 sites for commercial manufacturing of PHA

Restructuring of Antibióticos underway with prior management removed and new ownership emerging

Actively evaluating two sites for U.S.-based manufacturing facility

Product and market development

Potential for approximately $100MM revenue stream

Combining performance PHAs with PBAT, PBS, PLA and starches for high-value applications

© 2013 Metabolix 9

Cash Usage In Millions

*Numbers subject to rounding.

Q2

2013

Q1

2013

Q2

2012

First Half

2013

First Half

2012

Cash Used in

Operating Activities

$5.8 $ 8.5 $5.9 $14.3 $18.1

One-Time Uses

• Inventory Purchase $0.0 $ 0.0 $0.0 $0.0 $3.0

• Restructuring

Expenses $0.0 $ 0.0 $0.0 $0.0 $0.9

Normalized Cash

Usage (adjusted for

one-time uses)

$5.8 $ 8.5 $5.9 $14.3 $14.2

Other Cash Usage $0.2 $0.1 $0.2 $0.3 $0.4

Ending Cash &

Investment Balance $31.7 $ 37.7 $59.9 $31.7 $59.9

© 2013 Metabolix 10

Product Sales Revenue In Millions

Q1

2012

Q2

2012

Q3

2012

Q4

2012

Q1

2013

Q2

2013

First Half

2013

First Half

2012

Orders Shipped and

billed $0.0 $0.4 $0.7 $0.9 $0.7 $0.4 $1.1 $0.4

Deferred at period end1 0.0 0.0 (0.6) (0.8) (0.7) (0.3) (0.3) 0.0

Current quarter

shipments recognized $0.0 $0.4

$0.1 $0.1 $0.0 $0.1 $0.8 $0.4

Deferred orders

recognized 0.0 0.0 0.0 0.6 0.8 0.7 0.8 0.0

Total Product

Revenue

Recognized

$0.0 $0.4 $0.1 $0.7 $0.8 $0.8 $1.6 $0.4

1 The Company’s product revenue recognition policy is to defer recognition of

product revenue until the later of sixty days or receipt of customer payment.

*Numbers subject to rounding.

© 2013 Metabolix 11

Financial Results In Millions (except per share amounts)

Q2

2013

Q2

2012

First Half

2013

First Half

2012

Revenue $1.7 $0.9 $3.6 $40.2

Cost of Product

Revenues

$1.2 $0.4 $1.8 $0.5

R&D Expense $4.9 $5.0 $9.8 $11.1

SG&A Expense $3.4 $3.4 $6.7 $7.8

Net Income

(Loss)

Per share

($7.9)

($0.23)

($7.9)

($0.23)

($14.6)

($0.43)

$20.9

$0.61

*Numbers subject to rounding.

Q2 2013 Presentation

July 31, 2013

www.metabolix.com

@MetabolixInc